Amended Statement of Ownership (sc 13g/a)
February 14 2018 - 3:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE 13G
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
(Amendment
No. 1 )*
Catabasis
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock,
$0.001 par value
(Title of
Class of Securities)
14875P107
(CUSIP Number)
December 31,
2017
(Date of Event
Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
¨
Rule
13d-1(b)
¨
Rule
13d-1(c)
x
Rule 13d-1(d)
|
*
|
The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
|
The information required in the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 14875P107
|
|
Page 2 of 9
|
|
|
|
|
|
|
|
1.
|
|
Name of Reporting Persons
Advanced Technology Ventures VIII, L.P.
|
2.
|
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
x
1
(b)
¨
|
3.
|
|
SEC USE ONLY
|
4.
|
|
Citizenship or Place of Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:
|
|
5.
|
|
Sole Voting Power
0
|
|
6.
|
|
Shared Voting Power
1,133,943
2
|
|
7.
|
|
Sole Dispositive Power
0
|
|
8.
|
|
Shared Dispositive Power
1,133,943
2
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,133,943
2
|
10.
|
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
¨
|
11.
|
|
Percent of Class Represented by Amount in Row (9)
4.9%
3
|
12.
|
|
Type of Reporting Person (See Instructions)
PN
|
1
|
This Schedule 13G is being filed by Advanced Technology Ventures VIII, L.P. (“ATV VIII”) and ATV Associates VIII, L.L.C. (“ATVA VIII”), the general partner of ATV VIII.
|
|
|
2
|
Consists of shares held directly by ATV VIII.
|
|
|
3
|
This percentage is calculated based upon 23,083,177 shares of the Issuer’s common stock outstanding as of October 31, 2017, as set forth in the Issuer’s quarterly report on Form 10-Q
filed with the Securities and Exchange Commission on November 9, 2017.
|
CUSIP No. 14875P107
|
|
Page 3 of 9
|
|
|
|
|
|
|
|
1.
|
|
Name of Reporting Persons
ATV Associates VIII, L.L.C.
|
2.
|
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
x
1
(b)
¨
|
3.
|
|
SEC USE ONLY
|
4.
|
|
Citizenship or Place of Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:
|
|
5.
|
|
Sole Voting Power
0
|
|
6.
|
|
Shared Voting Power
1,133,943
2
|
|
7.
|
|
Sole Dispositive Power
0
|
|
8.
|
|
Shared Dispositive Power
1,133,943
2
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,133,943
2
|
10.
|
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
¨
|
11.
|
|
Percent of Class Represented by Amount in Row (9)
4.9%
3
|
12.
|
|
Type of Reporting Person (See Instructions)
OO
|
1
|
This Schedule 13G is being filed by Advanced Technology Ventures VIII, L.P. (“ATV VIII”) and ATV Associates VIII, L.L.C. (“ATVA VIII”), the general partner of ATV VIII.
|
|
|
2
|
Consists of shares held directly by ATV VIII.
|
|
|
3
|
This percentage is calculated based upon 23,083,177 shares of the Issuer’s common stock outstanding as of October 31, 2017, as set forth in the Issuer’s quarterly report on Form 10-Q
filed with the Securities and Exchange Commission on November 9, 2017.
|
CUSIP No. 14875P107
|
|
Page 4 of 9
|
Introductory Note: This Statement on Schedule 13G is
filed on behalf of Advanced Technology Ventures VIII, L.P., a Delaware limited partnership (“ATV VIII”) and ATV Associates
VIII, L.L.C., a Delaware limited liability company (“ATVA VIII”) in respect of shares of common stock of Catabasis
Pharmaceuticals, Inc.
Item 1.
Catabasis Pharmaceuticals, Inc.
|
(b)
|
Address of Issuer’s Principal Executive Offices
|
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139
Item 2.
|
(a)
|
Name of Person Filing
|
Advanced Technology Ventures VIII, L.P.
ATV Associates VIII, L.L.C.
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
500 Boylston Street, Suite 1380, Boston, MA 02116
Both of the entities are organized under the laws of Delaware.
|
(d)
|
Title of Class of Securities
|
Common Stock, $0.001 par value
14875P107
|
Item
3.
|
If
this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
|
Not applicable
CUSIP No. 14875P107
|
|
Page 5 of 9
|
|
(a)
|
Amount
Beneficially Owned as of December 31, 2017:
|
Advanced Technology Ventures VIII, L.P.
|
1,133,943 (1)
|
ATV Associates VIII, L.L.C.
|
1,133,943 (1)
|
|
(b)
|
Percent of Class as of December 31, 2017:
|
Advanced Technology Ventures VIII, L.P.
|
4.9%
|
ATV Associates VIII, L.L.C.
|
4.9%
|
|
(c)
|
Number of shares as to which the person has, as of December 31, 2017:
|
|
(i)
|
Sole power to vote or to direct the vote
|
Advanced Technology Ventures VIII, L.P.
|
0
|
ATV Associates VIII, L.L.C.
|
0
|
|
(ii)
|
Shared power to vote or to direct the vote
|
Advanced Technology Ventures VIII, L.P.
|
1,133,943 (1)
|
ATV Associates VIII, L.L.C.
|
1,133,943 (1)
|
|
(v)
|
Sole power to dispose or to direct the disposition of
|
Advanced Technology Ventures VIII, L.P.
|
0
|
ATV Associates VIII, L.L.C.
|
0
|
|
(iv)
|
Shared power to dispose or to direct the disposition of
|
Advanced Technology Ventures VIII, L.P.
|
1,133,943 (1)
|
ATV Associates VIII, L.L.C.
|
1,133,943 (1)
|
|
(1)
|
These shares are owned directly by ATV VIII.
|
|
Item 5.
|
Ownership of Five Percent
or Less of a Class
|
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check
the following.
x
|
Item
6.
|
Ownership
of More than Five Percent on Behalf of Another Person
|
Not Applicable
CUSIP No. 14875P107
|
|
Page 6 of 9
|
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|
Not Applicable
|
Item
8.
|
Identification
and Classification of Members of the Group
|
Not Applicable
|
Item
9.
|
Notice
of Dissolution of a Group
|
Not Applicable
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
Dated: February 14, 2018
ADVANCED TECHNOLOGY VENTURES VIII, L.P.
|
|
By:
|
ATV Associates VIII, L.L.C.
|
|
|
|
|
By:
|
/s/ Jean George
|
|
Name:
|
Jean George
|
|
Title:
|
Managing Director
|
|
|
|
|
ATV ASSOCIATES VIII, L.L.C.
|
|
|
|
|
By:
|
/s/ Jean George
|
|
Name:
|
Jean George
|
|
Title:
|
Managing Director
|
|
EXHIBITS
|
A:
|
Joint
Filing Agreement
|
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the
Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement
on Schedule 13G (including amendments thereto) with respect to the Common Stock of Catabasis Pharmaceuticals, Inc. and further
agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other
party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing
agreement may be signed in counterparts.
In evidence whereof, the undersigned have
caused this Agreement to be executed on their behalf this 14
th
day of February, 2018.
ADVANCED TECHNOLOGY VENTURES VIII, L.P.
|
|
By:
|
ATV Associates VIII, L.L.C.
|
|
|
|
|
By:
|
/s/ Jean George
|
|
Name:
|
Jean George
|
|
Title:
|
Managing Director
|
|
|
|
|
ATV ASSOCIATES VIII, L.L.C.
|
|
|
|
|
By:
|
/s/ Jean George
|
|
Name:
|
Jean George
|
|
Title:
|
Managing Director
|
|
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024